ELISA Kit for Anti-Ubiquitin Carboxyl Terminal Hydrolase L1 Antibody (Anti-UCHL1) 
PARK5; PGP9.5; Uch-L1; Neuron cytoplasmic protein 9.5; Ubiquitin thioesterase L1; Ubiquitin carboxyl-terminal hydrolase isozyme L1
- UOM
- FOB US$ 630.00 US$ 900.00 US$ 4,050.00 US$ 7,650.00 US$ 63,000.00
- Quantity
Overview
Properties
- Product No.AEG945Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antibody Detection.
Research use only - DownloadInstruction Manual
- CategoryEnzyme & Kinase
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of Anti-Ubiquitin Carboxyl Terminal Hydrolase L1 Antibody (Anti-UCHL1) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Ubiquitin Carboxyl Terminal Hydrolase L1 Antibody (Anti-UCHL1) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 87-95 | 92 |
| EDTA plasma(n=5) | 95-105 | 101 |
| heparin plasma(n=5) | 78-101 | 88 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Ubiquitin Carboxyl Terminal Hydrolase L1 Antibody (Anti-UCHL1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Ubiquitin Carboxyl Terminal Hydrolase L1 Antibody (Anti-UCHL1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Ubiquitin Carboxyl Terminal Hydrolase L1 Antibody (Anti-UCHL1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 94-102% | 84-95% | 87-104% | 80-97% |
| EDTA plasma(n=5) | 88-95% | 84-101% | 88-101% | 78-105% |
| heparin plasma(n=5) | 96-105% | 96-105% | 87-94% | 97-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 5 times;
5. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
6. Add 50µL Stop Solution. Read at 450nm immediately.
Test principle
The microtiter plate provided in this kit has been pre-coated with an antigen. Standards or samples are then added to the appropriate microtiter plate wells with a Horseradish Peroxidase (HRP)-conjugated secondary antibody. After TMB substrate solution is added, those wells that contain Anti-Ubiquitin Carboxyl Terminal Hydrolase L1 Antibody (Anti-UCHL1) will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Anti-Ubiquitin Carboxyl Terminal Hydrolase L1 Antibody (Anti-UCHL1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
Giveaways
Increment services
Citations
- Changes of ubiquitin C-terminal hydrolase-L1 levels in serum and urine of patients with white matter lesionsPubMed: 26232084
- Increased plasma UCH-L1 after aneurysmal subarachnoid hemorrhage is associated with unfavorable neurological outcomePubmed:26810533
- Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients after Carotid Endarterectomy mnstemps:135
- Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytespubmed:28667290
- Relationships between markers of neurologic and endothelial injury during critical illness and long-term cognitive impairment and disabilityPubmed:29523900
- Serum concentration of ubiquitin c-terminal hydrolase-L1 in detecting severity of traumatic brain injuryarticle:10.1088
- Peripheral blood biomarkers in aneurysmal subarachnoid hemorrhageISBN:978-952-03-0750-9
- Association of neuronal repair biomarkers with delirium among survivors of critical illnessPubmed: 31896448
- BDNF and IL-8, But Not UCHL-1 and IL-11, Are Markers of Brain Injury in Children Caused by Mild Head TraumaPubmed: 32987792